Aurobindo Pharma consolidated Q4 net profit up 79%
Aurobindo Pharma's strong financial performance in Q4FY24 and FY24, driven by revenue growth and net profit increase, was supported by market expansions, compliance enhancements, and regulatory adherence. The company's commitment to growth and operational stability remains firm.
Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.
